This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Authoring team

Clinical features typically develop 1-3 weeks after the drug or infection exposure (1).

There may be an initial prodromal phase which includes fever, arthralgia, malaise, headache, vomiting, diarrhoea, and myalgia (2). This is followed by severe mucocutaneous lesions which are bullous and ulcerating.

Skin lesions:

  • Skin lesions may appear as erythematous macules or as target lesions (2)
  • The typical target lesions contain 3 rings - a bright-pink or red inner ring, a lighter-pink outer ring, and a darker-pink outermost ring
  • skin detachment can be seen following these lesions which is the dominant clinical feature of SJS
  • skin lesions can be pruritic and painful (1)
  • lesions are seen in the extremities initially but may spread to involve the trunk as well (3)

Mucosal lesions:

  • Mucosal lesions are common and typically involve 2 or more sites such as oral, ocular, or genitourinary (1)

Sites of ulceration include:

  • mouth and fauces - causes a painful stomatitis
  • respiratory tract
  • gastrointestinal tract - erosions in the oesopahgus may cause dysphagia (1)
  • the urethra - thus a non-gonococcal urethritis
  • ocular - conjunctivitis, keratitis and corneal scarring (1)
  • the skin

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.